



Providing gold standard disinfection and decontamination technology through the design, development and global deployment of our state-of-the-art SteraMist product line and services

KEY FINANCIAL STATISTICS

\$25M
2020
ANNUAL
REVENUE

\$0.23
2020
DILUTED EPS

4.6X
CURRENT
RATIO
(MRQ)

16.8M
OUTSTANDING
SHARES

39%
INSIDE
OWNERSHIP

\$43M
MARKET CAP*
(As of 5.21.21)

INVESTMENT HIGHLIGHTS

CUTTING EDGE TECHNOLOGY

- TOMI BIT is the industry's ONLY low-percentage hydrogen peroxide solution capable of delivering six log kill with a dwell time of seconds
- No compromise to human health or adversely affecting medical and lab equipment

GLOBAL CUSTOMER BASE

- Hospitals, healthcare facilities, bio laboratories, state/local institutions, schools, restoration partners, sports organizations, offices, aerospace partners and more
- Rising demand from Asia, Europe & Middle East

SKILLED MANAGEMENT TEAM

- Visionary CEO Dr. Halden Shane
- Proven success delivering on business, operations and regulatory milestones
- Transformed TOMI's SteraMist Technology to gold standard of disinfections and decontamination technology

EXPANDING MARKET DEMAND

- Proliferation of MRSA, H1N1, C. Diff, etc. drove initial interest in SteraMist solutions
- Global pandemic has accelerated need for effective and fast acting disinfection solutions

STRONG PERFORMANCE

- Rapid sales acceleration driving consistent organic growth
- 2020 sales 3X greater than 2019
- Nearly 33% Adj. EBITDA margins

SUCCESSFUL BUSINESS MODEL

- Recurring revenue stream from sales of BIT solution
- High margin razor/razor blade model
- Capital efficient business infrastructure

DIVISIONS

HOSPITAL - HEALTHCARE



LIFE SCIENCES



TOMI SERVICE NETWORK



FOOD SAFETY





COMMERCIAL



UNIQUE NON-CORROSIVE TECHNOLOGY

SteraMist BIT is exclusive of toxic chemicals that are highly corrosive and hazardous, and contains no harmful silver ions



SANITIZATION → DISINFECTION → STERILIZATION

REGISTRATIONS & INTELLECTUAL PROPERTY



32

GRANTED
PATENTS

50

PATENTS
APPLICATIONS
WORLDWIDE

CUTTING EDGE IONIZED HYDROGEN PEROXIDE PROCESS

1. COLD PLASMA




7.8% hydrogen peroxide BIT Solution converts to iHP after passing through a cold plasma arc.

2. DISPERSION




iHP is carried throughout the mist, moving like a gas throughout the treated area.

3. CONTACT



iHP damages pathogenic organisms through oxidation of proteins, carbohydrates, and lipids.

4. DISRUPTION



Cellular disruptions and/or dysfunctions occur and allows for disinfection & decontamination in the targeted area.

MARKET DEMAND


Market is valued at nearly **\$19B** and expanding at a CAGR of **6.7%***

COVID-19 has sharply Increased the urgency and need for disinfection and decontamination products

Demand for effective disinfection products has grown consistently since 2014 as a result of the proliferation of **hospital acquired Infections and growing food safety concerns**

ONLY TOMI can deliver disinfection/decontamination that is highly effective (six log kill), fast acting and safe


* Source: Grand View Research



FINANCIAL RESULTS

\$ in 000's			
Income Statement	12/31/2018	12/31/2019	12/31/2020
Sales	\$5,585	\$6,347	\$25,028
Sales Growth	11.8%	13.7%	294%
Cost of Sales	(2,467)	(2,433)	(9,985)
Gross Profit	3,117	3,914	15,043
Gross Margin	55.8%	61.7%	60.1%
Operating Expenses	(6,188)	(5,997)	(10,534)
Income from Operations	(3,070)	(2,083)	4,509
Net Income	(3,230)	(2,298)	4,391
<i>Net Income Margin</i>	<i>(57.8%)</i>	<i>(36.8%)</i>	<i>18%</i>
<i>Diluted Earnings Per Share</i>	<i>(0.16)</i>	<i>(0.12)</i>	<i>0.23</i>

REPRESENTATIVES & DISTRIBUTORS AROUND THE GLOBE



CONTACT INFO

TOMI ENVIRONMENTAL SOLUTIONS, INC. | STERAMIST
8430 Spires Way Suite N
Frederick, MD 21701
TOMIMIST.COM

IMS INVESTOR RELATIONS
John Nesbett/Jen Belodeau
203-972-9200
jnesbett@imsinvestorrelations.com

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Certain written and oral statements made by us may constitute "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Forward-looking statements are identified by such words and phrases as "we expect," "expected to," "estimates," "estimated," "current outlook," "we look forward to," "would equate to," "projects," "projections," "projected to be," "anticipates," "anticipated," "we believe," "could be," and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this presentation.